An IL-2 mutein with decreased affinity to CD25 (mainly expressed on pulmonary endothelial cells and Treg cells) was developed to possess more effective tumor therapeutic effects than the wild-type IL-213,14. This evidence concerns the gene IL2RA and neoplasm.